Now accepting Telehealth appointments. Schedule a virtual visit.

Enrolling Studies


Bladder Cancer:

Altor Bioscience (Immunity Bio)   Protocol: QUILT-3.032

    - a study for patients with BCG unresponsive high-grade non-muscle invasive bladder cancer

Altor Bioscience (Immunity Bio)   Protocol: QUILT-2.005

    - a study for patients with high-grade non-muscle invasive bladder cancer who have never received BCG treatment


Prostate Cancer:

Bayer HealthCare Pharmaceuticals, Inc.      Protocol: 20609

      - a study to compare the effects of treatment between two medications on physical function and daily activity in men with castration-resistant prostate cancer

 Myriad Genetic Laboratories, Inc.     Protocol: URO-008

     - a long-term data collection registry study to evaluate treatment decisions and clinical outcomes in  men age 65 and older with favorable intermediate-risk prostate cancer 


Enteric Hyperoxaluria:

Allena Pharmaceuticals    Protocol: ALLN-177-302

      - kidney stone study to evaluate a medication to reduce oxalate excretion in patients with a history of  bariatric surgery, Crohn’s disease, short bowel or other malabsorption syndromes 


Overactive Bladder in Men:

Urovant Sciences   Protocol: URO-901-3005

      -  a study for males age 45 and older with overactive bladder symptoms currently on medication therapy for enlarged prostate


Stress Urinary Incontinence in Women: 

Solace Therapeutics, Inc       Protocol: Vesair Trial (VAPOR)

      - a study to evaluate a bladder control system for treating SUI in post-menopausal women


BPH (Benign Prostatic Hyperplasia):  

Urotronic, Inc     Protocol: PINNACLE

      - study to establish the safety and efficacy of the Optilume™ BPH Catheter System in treating BPH in males ages 50-80 years old


Uncomplicated UTI (Urinary Tract Infection):  

GlaxoSmithKline    Protocol: 212390

      - a study comparing Gepotidacin to Nitrofurantoin for the treatment of uncomplicated UTIs in females >12 years of age


Hypogonadism in Men:  

 Allergan, Inc       Protocol: Androderm

       - a study to determine 24 hour blood pressure at 16 weeks of treatment with Androderm patch


Repeat Prostate Biopsy: 

Exosome Diagnostics, Inc       Protocol: ECT2018-0001A

      - evaluation of ExoDx prostate test to correlate results with the outcome of prostate biopsies in men with a prior negative biopsy